SCHEMBL265296

SCHEMBL265296

CCN(CC)CCNCc1ccc(C(=O)Nc2ccc(Br)cc2C(=O)N/N=C/c2ccc(C)c(C)c2)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 3/20 0.39
SMN1; SMN2 Q16637 3/20 0.39
POLB P06746 4/20 0.39
CTDSP1 Q9GZU7 2/20 0.39
TDP1 Q9NUW8 2/20 0.39
PLEC Q15149 1/20 0.39
MAPT P10636 8/20 0.38
HPGD P15428 6/20 0.38
KDM4E B2RXH2 4/20 0.38
ALDH1A1 P00352 4/20 0.38
NPC1 O15118 3/20 0.38
MEN1 O00255 8/20 0.37
KMT2A Q03164 8/20 0.37
NPSR1 Q6W5P4 3/20 0.37
PKM P14618 2/20 0.37
ALOX12 P18054 1/20 0.37
LMNA P02545 2/20 0.37
CYP3A4 P08684 2/20 0.36
BLM P54132 1/20 0.36
TP53 P04637 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL265297 1.00 RAB9A (0.39) RAB9ASMN1; SMN2POLBCTDSP1TDP1
SCHEMBL267203 0.92 RAB9A (0.42) RAB9ASMN1; SMN2POLBCTDSP1TDP1
SCHEMBL267204 0.92 RAB9A (0.42) RAB9ASMN1; SMN2POLBCTDSP1TDP1
SCHEMBL267535 0.90 SMN1; SMN2 (0.53) RAB9ASMN1; SMN2POLBCTDSP1TDP1
SCHEMBL267536 0.90 SMN1; SMN2 (0.53) RAB9ASMN1; SMN2POLBCTDSP1TDP1
SCHEMBL266321 0.90 MEN1 (0.49) RAB9ASMN1; SMN2POLBCTDSP1TDP1
SCHEMBL266322 0.90 MEN1 (0.49) RAB9ASMN1; SMN2POLBCTDSP1TDP1
SCHEMBL269182 0.89 RAB9A (0.38) RAB9ASMN1; SMN2POLBCTDSP1TDP1
SCHEMBL269181 0.89 RAB9A (0.38) RAB9ASMN1; SMN2POLBCTDSP1TDP1
SCHEMBL266939 0.88 MAPT (0.53) RAB9ASMN1; SMN2POLBMAPTHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-05-10 US disclosed
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-05-10 US disclosed
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-05-10 US disclosed
US-8134015-B2 Compound inhibiting in vivo phosphorous transport and medicine containing the same KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-03-13 US disclosed
US-8134015-B2 Compound inhibiting in vivo phosphorous transport and medicine containing the same KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-03-13 US disclosed
US-8134015-B2 Compound inhibiting in vivo phosphorous transport and medicine containing the same KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-03-13 US disclosed
US-20060217426-A1 Compound inhibiting in vivo phosphorous transport and medicine containing the same KIRIN BEER KABUSHIKI KAISHA (JP) 2006-09-28 US disclosed
EP-1614676-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KIRIN BEER KABUSHIKI KAISHA (JP) 2006-01-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060217426-A1 Compound inhibiting in vivo phosphorous transport and medicine containing the same SLC10A6, SLC7A1, SLC10A1 RAB9A 883/4885SMN1; SMN2 3975/4885POLB 3843/4885
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME SLC34A1, SLC34A2, SLC20A2 RAB9A 1362/4885SMN1; SMN2 4253/4885POLB 3761/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.